Genmab A/S (GNMSF)
- Previous Close
268.61 - Open
275.10 - Bid 268.65 x 1200
- Ask 280.00 x 28000
- Day's Range
268.61 - 275.10 - 52 Week Range
262.00 - 421.26 - Volume
38 - Avg. Volume
525 - Market Cap (intraday)
17.89B - Beta (5Y Monthly) 0.81
- PE Ratio (TTM)
22.22 - EPS (TTM)
12.09 - Earnings Date Aug 1, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
www.genmab.comRecent News: GNMSF
Performance Overview: GNMSF
Trailing total returns as of 6/10/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GNMSF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GNMSF
Valuation Measures
Market Cap
18.10B
Enterprise Value
13.93B
Trailing P/E
22.55
Forward P/E
23.75
PEG Ratio (5yr expected)
1.15
Price/Sales (ttm)
6.93
Price/Book (mrq)
3.70
Enterprise Value/Revenue
5.37
Enterprise Value/EBITDA
13.41
Financial Highlights
Profitability and Income Statement
Profit Margin
30.74%
Return on Assets (ttm)
10.63%
Return on Equity (ttm)
18.32%
Revenue (ttm)
17.78B
Net Income Avi to Common (ttm)
5.47B
Diluted EPS (ttm)
12.09
Balance Sheet and Cash Flow
Total Cash (mrq)
29.58B
Total Debt/Equity (mrq)
3.11%
Levered Free Cash Flow (ttm)
3.83B
Research Analysis: GNMSF
Company Insights: GNMSF
GNMSF does not have Company Insights